JP Morgan Chase’s Regulus Therapeutics RGLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-74,517
| Closed | -$130K | – | 7549 |
|
|
2025
Q1 | $130K | Sell |
74,517
-115,940
| -61% | -$153K | ﹤0.01% | 5440 |
|
|
2024
Q4 | $301K | Buy |
190,457
+111,485
| +141% | +$171K | ﹤0.01% | 5293 |
|
|
2024
Q3 | $124K | Buy |
78,972
+52,059
| +193% | +$86.1K | ﹤0.01% | 5610 |
|
|
2024
Q2 | $48K | Buy |
26,913
+7,171
| +36% | +$16.6K | ﹤0.01% | 5878 |
|
|
2024
Q1 | $56.9K | Buy |
19,742
+19,713
| +67,976% | +$32.1K | ﹤0.01% | 5886 |
|
|
2023
Q4 | $37 | Buy |
29
+9
| +45% | +$12 | ﹤0.01% | 7250 |
|
|
2023
Q3 | $28 | Buy |
+20
| New | +$29 | ﹤0.01% | 7103 |
|
|
2019
Q4 | – | Sell |
-7
| Closed | – | – | 5853 |
|
|
2019
Q3 | $0 | Hold |
7
| – | – | ﹤0.01% | 5916 |
|
|
2019
Q2 | $0 | Buy |
+7
| New | +$81 | ﹤0.01% | 5968 |
|
|
2018
Q4 | – | Sell |
-7
| Closed | – | – | 5894 |
|
|
2018
Q3 | $0 | Hold |
7
| – | – | ﹤0.01% | 5792 |
|
|
2018
Q2 | $1K | Buy |
+7
| New | +$579 | ﹤0.01% | 5492 |
|
|
2017
Q4 | – | Sell |
-63
| Closed | -$10K | – | 5554 |
|
|
2017
Q3 | $10K | Sell |
63
-77
| -55% | -$9.68K | ﹤0.01% | 4722 |
|
|
2017
Q2 | $17K | Buy |
+140
| New | +$23.4K | ﹤0.01% | 4570 |
|
Other funds holding RGLS
JP Morgan Chase's RGLS Position: Q2 2025 in Review
JP Morgan Chase sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 74,517 shares — an estimated $130K sold.
JP Morgan Chase first reported a position in RGLS in Q2 2017 and held it in 13 quarters. The position peaked at $301K in Q4 2024. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.
- JP Morgan Chase reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
- JP Morgan Chase sold 74,517 Regulus Therapeutics shares in Q2 2025, an estimated $130K.
- JP Morgan Chase first reported a position in Regulus Therapeutics in Q2 2017 and held it in 13 quarters.
- JP Morgan Chase's Regulus Therapeutics position peaked at $301K in Q4 2024.
- 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.
Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.